Do you suffer from depression?
About the study ITI-007-502
In study ITI-007-502, we investigate an investigational drug, also called "study drug". The study will investigate how well the study drug works in people with depression who have not responded well to ongoing antidepressant drug treatment.
Why is this study important?
Depression is a common mental illness, but some people with depression do not respond well to antidepressant drug treatment. This study examines the study drug to see how it works in people with depression when it is used alongside their existing antidepressants.
What does the study entail?
If you participate, you will be in the study ITI-007-502 for up to nine weeks. You will:
- continue to take your existing antidepressant medication
- take either the study drug or a placebo (together called “study medication”) – Placebo looks like the study drug but contains no active substances
- undergo some tests to check your general state of health
- answer questions about your psychological symptoms.
Who can participate?
You or someone you know may be able to participate if you/that person:
- is between 18 and 65 years old
- have a confirmed diagnosis of major depressive disorder, with an ongoing major depressive episode that began between eight weeks and 18 months ago
- have not experienced any significant improvement from existing antidepressant drug treatment.
Is there anything else I need to think about?
- The study team will explain the possible benefits and risks of the study.
- You do not have to participate in the study if you do not want to.
- If you choose to participate, you can cancel your participation in the study at any time.
- You will not be paid to participate in this study, but you may be reimbursed for reasonable travel expenses while you participate.
- All study-related medications and tests and examinations are provided at no cost to you.
- A team of doctors and nurses will carefully monitor your health during the course of the study.
- The study has been approved by the Institutional Review Board (IRB)/Ethics Committee which protects the rights, safety and well-being of the participants.
Interested?
To learn more about this study, contact:
Ewa Karlsson, phone 0732-300 450 or email ewa.karlsson@probare.se